# Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)

> **NCT00617305** · PHASE4 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 38 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Ambrisentan
- **DRUG:** Placebo
- **DRUG:** Sildenafil
- **DRUG:** Tadalafil

## Key facts

- **NCT ID:** NCT00617305
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2011-02
- **Final completion:** 2011-07
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2012-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00617305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00617305, "Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00617305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*